PE-22-28 vs BNP (B-type Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PE-22-28
PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.
Full details →BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Side-by-Side Comparison
| Aspect | PE-22-28 | BNP (B-type Natriuretic Peptide) |
|---|---|---|
| Mechanism | Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways. | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. |
| Typical Dosage | Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established. | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. |
| Administration | Intranasal administration preferred for CNS delivery. Research compound with limited human use data. | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. |
| Side Effects | Very limited human data. Primarily studied in animal models for safety and efficacy. | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. |
| Best For |